Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment: data from the FLAME trial
Rationale: Post hoc analyses suggest that blood eosinophils have potential as a predictive biomarker of inhaled corticosteroid efficacy in the management of chronic obstructive pulmonary disease (COPD).Objectives: We prospectively investigated the value of blood eosinophils as a predictor of respons...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
March 9, 2017
|
| In: |
American journal of respiratory and critical care medicine
Year: 2017, Jahrgang: 195, Heft: 9, Pages: 1189-1197 |
| ISSN: | 1535-4970 |
| DOI: | 10.1164/rccm.201701-0193OC |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1164/rccm.201701-0193OC Verlag, kostenfrei, Volltext: https://www.atsjournals.org/doi/abs/10.1164/rccm.201701-0193OC 
|
| Verfasserangaben: | Nicolas Roche, Kenneth R. Chapman, Claus F. Vogelmeier, Felix J.F. Herth, Chau Thach, Robert Fogel, Petter Olsson, Francesco Patalano, Donald Banerji, and Jadwiga A. Wedzicha |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1577459547 | ||
| 003 | DE-627 | ||
| 005 | 20230426230626.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180710s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1164/rccm.201701-0193OC |2 doi | |
| 035 | |a (DE-627)1577459547 | ||
| 035 | |a (DE-576)507459547 | ||
| 035 | |a (DE-599)BSZ507459547 | ||
| 035 | |a (OCoLC)1341013543 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Roche, Nicolas |d 1984- |e VerfasserIn |0 (DE-588)1045325686 |0 (DE-627)774090375 |0 (DE-576)398939225 |4 aut | |
| 245 | 1 | 0 | |a Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment |b data from the FLAME trial |c Nicolas Roche, Kenneth R. Chapman, Claus F. Vogelmeier, Felix J.F. Herth, Chau Thach, Robert Fogel, Petter Olsson, Francesco Patalano, Donald Banerji, and Jadwiga A. Wedzicha |
| 264 | 1 | |c March 9, 2017 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 10.07.2018 | ||
| 520 | |a Rationale: Post hoc analyses suggest that blood eosinophils have potential as a predictive biomarker of inhaled corticosteroid efficacy in the management of chronic obstructive pulmonary disease (COPD).Objectives: We prospectively investigated the value of blood eosinophils as a predictor of responsiveness to an inhaled corticosteroid/long-acting β2-agonist combination versus a long-acting β2-agonist/long-acting muscarinic antagonist combination for exacerbation prevention.Methods: We conducted prespecified analyses of data from the FLAME (Effect of Indacaterol Glycopyronium vs Fluticasone Salmeterol on COPD Exacerbations) study, which compared once-daily long-acting β2-agonist/long-acting muscarinic antagonist indacaterol/glycopyrronium 110/50 μg with twice-daily long-acting β2-agonist/inhaled corticosteroid salmeterol/fluticasone combination 50/500 μg in patients with one or more exacerbations in the preceding year. Subsequent post hoc analyses were conducted to address further cutoffs and endpoints.Measurements and Main Results: We compared treatment efficacy according to blood eosinophil percentage (<2% and ≥2%, <3% and ≥3%, and <5% and ≥5%) and absolute blood eosinophil count (<150 cells/μl, 150 to <300 cells/μl, and ≥300 cells/μl). Indacaterol/glycopyrronium was significantly superior to salmeterol/fluticasone for the prevention of exacerbations (all severities, or moderate or severe) in the <2%, ≥2%, <3%, <5%, and <150 cells/μl subgroups, and at no cutoff was salmeterol/fluticasone superior to indacaterol/glycopyrronium. Furthermore, the rate of moderate or severe exacerbations did not increase with increasing blood eosinophils. The incidence of pneumonia was higher in patients receiving salmeterol/fluticasone than indacaterol/glycopyrronium in both the <2% and ≥2% subgroups.Conclusions: Our prospective analyses indicate that indacaterol/glycopyrronium provides superior or similar benefits over salmeterol/fluticasone regardless of blood eosinophil levels in patients with COPD.Clinical trial registered with www.clinicaltrials.gov (NCT01782326). | ||
| 700 | 1 | |a Herth, Felix |e VerfasserIn |0 (DE-588)1016095236 |0 (DE-627)705477568 |0 (DE-576)351509925 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of respiratory and critical care medicine |d New York, NY : American Thoracic Society, 1959 |g 195(2017), 9, Seite 1189-1197 |h Online-Ressource |w (DE-627)26688492X |w (DE-600)1468352-0 |w (DE-576)075961563 |x 1535-4970 |7 nnas |a Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment data from the FLAME trial |
| 773 | 1 | 8 | |g volume:195 |g year:2017 |g number:9 |g pages:1189-1197 |g extent:9 |a Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment data from the FLAME trial |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1164/rccm.201701-0193OC |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.atsjournals.org/doi/abs/10.1164/rccm.201701-0193OC |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180710 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 1016095236 |a Herth, Felix |m 1016095236:Herth, Felix |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PH1016095236 |e 950000PH1016095236 |e 950900PH1016095236 |e 50000PH1016095236 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 4 | ||
| 999 | |a KXP-PPN1577459547 |e 3017216756 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"9 S."}],"recId":"1577459547","origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"March 9, 2017"}],"person":[{"role":"aut","given":"Nicolas","family":"Roche","display":"Roche, Nicolas"},{"family":"Herth","given":"Felix","role":"aut","display":"Herth, Felix"}],"relHost":[{"origin":[{"publisher":"American Thoracic Society ; American Lung Association","dateIssuedKey":"1959","dateIssuedDisp":"1959-","publisherPlace":"New York, NY ; New York, NY"}],"title":[{"title":"American journal of respiratory and critical care medicine","title_sort":"American journal of respiratory and critical care medicine","subtitle":"AJRCCM ; an official journal of the American Thoracic Society, Medical Section of the Lung Association"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"note":["Gesehen am 17.01.2022"],"recId":"26688492X","physDesc":[{"extent":"Online-Ressource"}],"disp":"Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment data from the FLAME trialAmerican journal of respiratory and critical care medicine","titleAlt":[{"title":"AJRCCM online"},{"title":"AJRCCM"},{"title":"American review of respiratory diseases"}],"pubHistory":["80.1959 -"],"corporate":[{"role":"isb","display":"American Thoracic Society"}],"id":{"issn":["1535-4970"],"eki":["26688492X"],"zdb":["1468352-0"]},"part":{"volume":"195","year":"2017","issue":"9","extent":"9","text":"195(2017), 9, Seite 1189-1197","pages":"1189-1197"}}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 10.07.2018"],"title":[{"title":"Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment","title_sort":"Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment","subtitle":"data from the FLAME trial"}],"name":{"displayForm":["Nicolas Roche, Kenneth R. Chapman, Claus F. Vogelmeier, Felix J.F. Herth, Chau Thach, Robert Fogel, Petter Olsson, Francesco Patalano, Donald Banerji, and Jadwiga A. Wedzicha"]},"id":{"doi":["10.1164/rccm.201701-0193OC"],"eki":["1577459547"]}} | ||
| SRT | |a ROCHENICOLBLOODEOSIN9201 | ||